Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
Jayastu SenapatiHagop M KantarjianAlexandre BazinetPatrick K RevilleNicholas James ShortNaval G DaverGautam BorthakurAlex BatallerElias J JabbourCourtney D D DiNardoFady Gh HaddadKoiji SasakiUday R PopatBetül OranAmin M AlousiSanam LoghaviElizabeth ShpallGuillermo Garcia ManeroFarhad RavandiTapan Mahendra KadiaPublished in: Cancer (2024)
In conclusion, treatment with CLAD/LDAC/Ven was associated with favorable outcomes in older patients who underwent subsequent allogeneic SCT. The OS was comparable to that with intensive chemotherapy followed by allogeneic SCT, but the CIR rate was significantly lower.
Keyphrases
- stem cell transplantation
- high dose
- low dose
- acute myeloid leukemia
- patients undergoing
- locally advanced
- physical activity
- allogeneic hematopoietic stem cell transplantation
- type diabetes
- middle aged
- metabolic syndrome
- squamous cell carcinoma
- rectal cancer
- radiation therapy
- combination therapy
- mesenchymal stem cells